"Uncaging" the artery with a novel metallic coronary device

EuroIntervention 2020;16:e957-e959. DOI: 10.4244/EIJV16I12A175

Takeshi Kimura
Takeshi Kimura1, MD; Ko Yamamoto1, MD
1. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan

The established mechanisms of long-term adverse events related to coronary stenting include thrombosis, neointimal hyperplasia, and persistent inflammation/neoatherosclerosis, which could be closely related to the persistent presence of metallic stents in the vessel wall (Figure 1). Fully bioresorbable vascular scaffolds (BVS) have been developed to overcome the shortcomings of metallic coronary stents that are persistently present with or without polymer in the vessel wall. However, the Absorb™ BVS (Abbott Vascular, Santa Clara, CA, USA) was demonstrated to be inferior to new-generation metallic drug-eluting stents (DES) due to a higher rate of device thrombosis before complete resorption of the ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Coronary re-access after redo TAVI: a proposed classification to simplify evaluation

Latest news